Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
CheckMate 153 trial: how long should nivolumab be taken for?
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
Immuno-oncology agents plus tyrosine kinase inhibitors?